Terasin

Quick links to important sections

Terasin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Terasin

Property Description
Active ingredient Terazosin Hydrochloride
Form Oral Capsule, Tablet
Pharmacological class Alpha-1 Adrenergic Receptor Antagonist (Alpha-Blocker)
General purpose Reduce vascular resistance, improve urinary flow
Origin Synthetic (Quinazoline derivative)

Terasin’s Classification: What is an Alpha-1 Blocker?

Terasin is a prescription-only, synthetic oral medication whose active compound is Terazosin Hydrochloride, which is chemically defined as a quinazoline derivative. It is formally classified as a long-acting, selective alpha-1 adrenergic receptor antagonist, commonly known as an alpha-1 blocker.

The designation as an alpha-1 blocker relates to the drug’s role in mediating effects across the cardiovascular and urologic systems. This classification signifies that Terasin operates by selectively blocking the signals transmitted through the alpha-1 receptors found in smooth muscle tissues. By interrupting these specific signals that promote muscle contraction, the drug induces muscle relaxation, which is the key mechanism distinguishing it from agents that manage pressure via other pathways.

What is the General Purpose of Terasin?

The general purpose of Terasin is to achieve therapeutic benefits through the systemic relaxation of smooth muscle tissue, resulting in vasodilation and reduced tension in the lower urinary tract.

This systemic action serves two high-level functions: the relaxation of smooth muscles lining arterial walls generally aids in reducing peripheral vascular resistance, facilitating the lowering of elevated blood pressure. Furthermore, this relaxing effect in the bladder neck and prostate area is noted for generally helping to alleviate obstruction, thereby improving functional flow. Terasin is supplied for oral administration, typically available as a capsule or tablet, supporting the consistent, long-term management necessary for its intended physiological effects.

Regulatory References

  1. Terazosin - StatPearls (NIH)

What side effects are possible with Terasin?

Possible Side Effects and Safety Information: Terasin

The safety profile of Terazosin Hydrochloride (Terasin), an alpha-1 blocker, is defined by regulatory classifications of adverse reactions, which often relate to its systemic effects on blood pressure and smooth muscle.

Frequency-Classified Adverse Reactions

The incidence of documented adverse effects is classified according to standard regulatory definitions:

  • Common (affecting up to 1 in 10 patients): These frequently reported effects include dizziness, headache, somnolence (drowsiness), fatigue/asthenia, nasal congestion, palpitations, and postural hypotension (low blood pressure upon standing). Blurred vision and peripheral edema are also listed as common.
  • Uncommon (affecting up to 1 in 100 patients): Reactions less frequently reported include syncope (fainting), impotence, and weight gain.

Serious Adverse Reactions and Safety Constraints

Official regulatory documents highlight specific reactions classified as serious or clinically significant. These include Syncope, which is a significant drop in blood pressure that can lead to fainting, and Priapism, a prolonged, painful erection that requires urgent clinical awareness. The drug is also associated with Intraoperative Floppy Iris Syndrome (IFIS), which is a complication observed during cataract surgery. Orthostatic effects, such as dizziness and syncope, are most likely to occur shortly after the initial dose, upon reinitiation of therapy, or during dose escalation.

Safety constraints prohibit the use of Terasin in individuals with a known hypersensitivity to quinazolines. Caution is advised for use in patients with impaired hepatic function, and the safety and effectiveness have not been established in pediatric patients.

Overdose and Emergency Response

Overdose of Terasin (Terazosin Hydrochloride) is primarily described in regulatory documents as an exaggeration of the drug’s intended pharmacological effects, leading to severe cardiovascular symptoms.

Documented Overdose Manifestations and Actions

Overdose Entity Official Regulatory Statement
Documented Presentations Symptoms may include severe hypotension, fainting (syncope), dizziness, lightheadedness, palpitations, and rapid heartbeat (tachycardia) [NIH/MedlinePlus, HPRA].
Severe Outcomes The excessive drop in blood pressure can result in hemodynamic instability, which carries the risk of secondary injuries such as cerebral ischemia [INCHEM, NIH/StatPearls].
Help-Seeking Mandate Seek immediate emergency medical attention or contact a Poison Control Centre immediately [NIH/MedlinePlus, Health Canada]. If the affected individual has collapsed, has trouble breathing, or cannot be awakened, immediately call emergency services [NIH/MedlinePlus].
Antidote Status No specific antidote is known for Terazosin toxicity [INCHEM, NIH/StatPearls].

Overdose Management

The management of overdose is explicitly designated as symptomatic and supportive. Restoration of blood pressure may require placing the patient in a supine position and administering I.V. fluids [INCHEM]. If these measures are inadequate, vasopressors such as dopamine or noradrenaline may be required [INCHEM]. Furthermore, continuous monitoring of heart rate, blood pressure, and renal function is advised, but dialysis is unlikely to be of benefit due to the drug’s high protein binding [INCHEM].

Therapeutic Uses of Terasin

What Terasin Treats: Main Uses and Benefits

Terasin is a medication commonly used to help manage two key conditions: symptoms related to Benign Prostatic Hyperplasia (BPH) and Essential Hypertension (high blood pressure). Its therapeutic applications focus on easing the symptoms that create noticeable physiological strain in these two domains.


Relief of Obstructive and Irritative Urinary Symptoms

Terasin is applied in clinical settings relevant to the symptoms that interfere with daily functioning associated with BPH in men. It helps address symptom clusters like a weak urine flow, straining, or the sensation of incomplete emptying, alongside irritative patterns such as urgency and frequent urination, including bothersome nocturia. This therapeutic support is relevant for managing symptoms linked to organ-specific functional stress, contributing to improved day-to-day comfort and flow and supports patients with managing functional stability.


Supportive Management of Essential High Blood Pressure

The medication is applied in clinical settings relevant to the long-term control of essential hypertension. It is commonly used to provide supportive therapeutic benefit by addressing elevated systemic vascular pressure, often as part of a sustained management plan. This application assists with maintaining a stable pressure range, which contributes to easing the overall symptom load associated with heightened physiological stress. This supportive action helps maintain a sense of stability and contributes to easing the overall symptom load.

Quick Fact: Relief for Obstructive Symptoms
Symptom Category: Lower Urinary Tract Symptoms (LUTS) in men.
Main Benefit: Supports better overall functional comfort and flow.
Scenario: Long-term management of bothersome urinary discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Terasin's official eligibility is strictly defined by regulatory documents, distinguishing between approved, contraindicated, and conditionally restricted populations.

Populations Who Must Not Use Terasin (Contraindicated)

Use is absolutely contraindicated in patients with a known hypersensitivity (allergy) to terazosin or any similar alpha-1 adrenergic receptor antagonist. The medication must also not be used by patients with a history of micturition syncope (fainting associated with urination).

Approved and Restricted Populations

Terasin is formally approved for adult males (for Benign Prostatic Hyperplasia) and adults of both sexes (for Hypertension).

  • Age-Related Eligibility: Safety and effectiveness have not been established for pediatric patients (under 18 years). Use in older adults requires caution due to the documented risk of severe postural hypotension and related falls.
  • Reproductive Status: Regulatory data are insufficient regarding use in pregnant women; use is conditional on the potential benefit justifying the risk to the fetus. Caution is recommended for nursing mothers as drug excretion into breast milk is unknown.
  • Comorbidity Pre-Screening: For the BPH indication, the official label requires that the presence of prostate carcinoma must be ruled out before and during administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Category Documented Interaction Entities
Medicinal product categories with documented interactions Antihypertensive Agents (e.g., Diuretics, Beta-blockers, Calcium Channel Blockers), Phosphodiesterase Type 5 (PDE-5) Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), General Anesthetics.
Specific interacting medicines (if explicitly listed) Verapamil (documented increase in Terasin exposure), Sildenafil, Tadalafil, Vardenafil (documented risk of hypotension).
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic (PD) Interaction: Documented additive blood pressure lowering effect. Pharmacokinetic (PK) Interaction: Documented increase in systemic exposure ( AUC) of Terasin.
Timing-based interaction rules (if applicable) Risk management for PDE-5 inhibitors requires the patient to be stable on Terasin therapy before initiation of the co-administered agent.
Population-specific interaction notes (if applicable) Caution is advised in patients with significantly impaired hepatic function due to the potential for drug accumulation.
Interaction-related restrictions Alcohol use may increase the risk of side effects such as dizziness, a symptom related to hypotension.

Interaction Classifications (High-Level)

Classification Description (As Defined in Official Documents)
Interaction severity classification Use-with-Caution Combinations: Required caution due to enhanced risk of symptomatic hypotension (PD-interaction) or altered drug levels (PK-interaction).
Regulatory basis FDA Prescribing Information, European Summary of Product Characteristics (SmPC), NIH MedlinePlus.
Interaction-context constraints Interactions often define the required management of co-administration rather than absolute prohibition.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with other antihypertensive agents can lead to an additive blood pressure lowering effect.
  • Use with PDE-5 Inhibitors may result in symptomatic hypotension due to additive vasodilatory effects.
  • The co-administration of Verapamil has been formally shown to increase the systemic exposure ( AUC) of Terasin.
  • The hypotensive effects of Terasin may be antagonized (decreased) when administered with NSAIDs.

Connection to the overall interaction profile:

Regulatory documents define Terasin's interaction structure primarily through its alpha-1 blocker classification, leading to extensive documentation of pharmacodynamic interactions with other vasodilating and antihypertensive drug classes. A secondary but formally documented component involves pharmacokinetic interactions, where specific agents are listed for their measurable effect on Terasin's systemic exposure ( AUC). This structure establishes co-administration risk management constraints.

Mechanism of Action

Terazosin Hydrochloride is a pharmacologic agent that acts via the targeted modulation of the Alpha-1 Adrenergic Receptor (alpha1 AR) system. It functions as a competitive antagonist, physically blocking alpha1 receptor sites on smooth muscle cells to prevent activation by sympathetic nervous system signaling molecules. This blockade effectively halts the G q/11 protein cascade, preventing the subsequent increase in intracellular calcium necessary for muscle contraction. This molecular mechanism produces two primary physiological consequences in distinct tissue systems.

Blocking alpha1 Receptors to Reduce Vascular Tone

Interruption of sympathetic signaling in the arterioles leads to vasodilation, a widening of the blood vessels. This sustained physiological change reduces the overall resistance within the circulatory system, known as the Total Peripheral Vascular Resistance (TPR), directly altering the mechanical resistance presented to the cardiovascular system.

Modulating Muscle Tone in the Lower Urinary Tract

By blocking the alpha1 ARs highly concentrated in the prostate and bladder neck, Terasin reduces the dynamic tension exerted by the muscle fibers surrounding the urethra. This localized relaxation decreases the functional resistance to outflow, modulating the mechanical state of the lower urinary tract. The mechanism exclusively targets muscle tone and is not involved in reducing the fixed, anatomical mass of the prostate gland.

Dosage and Administration Information

How to Use Terasin (Terazosin Hydrochloride)

This section describes the administration and official dosing regimens for Terasin (Terazosin Hydrochloride). It does not contain safety information or therapeutic claims.


Administration Protocol

The approved route of administration for Terasin is oral via capsules, tablets, or an oral solution. The medicine is generally taken once daily; however, for hypertension management, the dose may be divided into a twice-daily regimen if the response significantly diminishes after 24 hours. Terasin may be taken with or without food.

Initial Administration: The starting dose for both approved indications is strictly 1 mg once daily and must not be exceeded upon therapy initiation. This initial dose, and any subsequent dosage increases, should be taken at bedtime.


Official Dosing and Titration

Treatment requires a slow, stepwise titration to the maintenance dose, typically at weekly intervals.

Indication Usual Maintenance Dose Range Maximum Daily Dose
Benign Prostatic Hyperplasia (BPH) 5 mg to 10 mg once daily 20 mg once daily
Essential Hypertension 1 mg to 5 mg once daily 20 mg once daily

Special Procedural Rules

  • Interruption of Therapy: If Terasin is discontinued for several days or longer, therapy must be re-instituted by returning to the initial 1 mg dose and repeating the full titration schedule.
  • Hepatic Impairment: Dosing requires particular caution and careful titration in patients with impaired liver function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Terasin

The clinical research for Terasin (Terazosin Hydrochloride) is documented through formal studies, primarily randomized, double-blind, placebo-controlled trials (RCTs). These studies were the main type of research used to collect initial data for regulatory review. Regulatory sources rely on these findings to understand the research base for the two main conditions Terasin was studied for: symptomatic Benign Prostatic Hyperplasia (BPH) and Essential Hypertension.


Evidence for Symptomatic Benign Prostatic Hyperplasia (BPH)

Research exploring Terasin's application in men with symptomatic BPH is founded upon placebo-controlled trials. These studies were designed to evaluate outcomes related to the physical discomfort and functional limitations associated with conditions marked by functional limitations.

How symptoms and functional flow were studied

The clinical trials enrolled adult men experiencing the effects of BPH. Research examined outcomes related to patient-reported discomfort using validated tools like the International Prostate Symptom Score (IPSS), which is used in research exploring how symptoms change over time. Studies also monitored objective functional measures, most importantly the Peak Urinary Flow Rate (Q max), a measure of the speed of urination.

Study reports described differences in the average change of the IPSS symptom scores and the Q max functional measure when comparing the active treatment group and the placebo group. Systematic reviews summarize these findings, which help contextualize how patients reported their experience during the study period. Some reports described patterns where differences were maintained after the initial weeks of study. Studies exploring long-term symptom change also reported on how this pattern of change related to other treatment options studied in the same context.

Evidence for Essential Hypertension (High Blood Pressure)

Terasin was evaluated in research for its role in managing essential hypertension, which is a condition involving systemic physiological strain. Initial studies for this use also employed randomized, controlled designs.

Blood pressure outcomes measured in trials

Research explored short-term symptom changes by monitoring the reduction in blood pressure measurements in adult patients with mild-to-moderate hypertension. Studies monitored changes in both Supine Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP). Data show patterns related to a dose-response relationship, where changes in pressure measurements were observed as the study dose was gradually increased. Studies monitored blood pressure responses in both SBP and DBP that were reported to be greater than those recorded in the placebo-treated groups. This type of research contributes to the broader evidence landscape by providing insight into short-term changes in physiological strain. Some trials described that the magnitude of blood pressure changes was comparable across racial subgroups.

Long-Term Studies and Durability of Response

Beyond the initial controlled trials, long-term observational research has been performed to examine the sustained response patterns of Terasin. These follow-up studies, which was observed in non-placebo-controlled settings for up to 3 to 4.5 years, provided an extended look at patients who had been transferred from the initial controlled studies. These open-label studies focused on describing the maintenance of the initial reported change in symptom scores and peak flow rates over several years.

However, long-term effects are not fully established when considering the progression of BPH itself, such as preventing the risk of acute urinary retention or the need for surgery. The most rigorous evidence from controlled trials remains focused on the short-term time frames, while the very long-term reports lack a concurrent control group for comparison.

What Research Remains Uncertain or Limited

Despite the existence of controlled trials and long-term observational data, certain aspects of Terasin's research profile are still considered limited or uncertain by regulatory and scientific bodies.

Specifically, there is limited information for long-term outcomes regarding the prevention of BPH progression—evidence for this outcome is generally associated with other drug classes. For hypertension, while research documents the blood pressure-lowering effect, the data on cardiovascular morbidity and mortality reduction is considered more established for certain other antihypertensive drug classes. Research does not determine whether an individual will respond similarly to the group patterns reported in the studies, and results apply only to the populations studied.

Key Studies & References

  1. Terazosin - StatPearls - NCBI Bookshelf (Review of Indications, Mechanism, and Trials)
  2. Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial

Frequently Asked Questions (FAQ)

Common questions about Terasin (FAQ)


Q: How quickly does Terasin start working?

Studies indicate that changes in blood pressure have been observed within 15 minutes following administration for the management of hypertension. For the treatment of Benign Prostatic Hyperplasia (BPH) symptoms, improvements are described as appearing more gradually, typically over several weeks of continuous therapy.


Q: How long does the effect of a Terasin dose last?

Terasin is generally prescribed for once-daily use. Clinical data documented that blood pressure lowering effects were present at the end of the 24-hour dosing interval, supporting the once-daily regimen.


Q: What happens if I forget to take a dose of Terasin?

The official product information does not specify a procedure for a single missed dose. However, if the medicine is discontinued for several days or longer, official guidelines state that treatment must be re-instituted using the initial low dose and repeating the full dose adjustment schedule.


Q: Is Terasin safe to use during pregnancy? (Descriptive inquiry)

Regulatory documents state that there are insufficient data on the use of Terasin in pregnant women to determine a drug-related risk to the fetus. Official guidance indicates that use is conditional on the potential benefit justifying the potential risk, as assessed by a healthcare professional. It is also unknown whether Terasin is excreted into breast milk.


Q: What does 'contraindication' mean in the context of Terasin?

A contraindication is a circumstance where a medicine must absolutely not be used. For Terasin, this applies to individuals with a known hypersensitivity (allergy) to the drug or similar medicines, or those with a history of micturition syncope (fainting associated with urination).


Q: What happens when Terasin is stopped?

Stopping Terasin can lead to a return of the symptoms it was used to manage. If the drug is discontinued for several days or more, official documents state that therapy must be re-instituted at the initial 1 mg dose and the full titration process repeated.


Q: Can people with kidney problems use Terasin?

Official documentation indicates that impaired kidney function has no significant effect on the elimination of Terasin. Therefore, typically, no dosage adjustment is required for this population based on current regulatory information.


Q: Can people with liver problems use Terasin?

Official documents advise that Terasin should be used with caution in individuals with impaired liver function. A careful titration of the dosage is noted as necessary for this patient group due to the potential for drug accumulation.


Q: How is Terasin described as working in the body?

Terasin is a selective alpha-1 adrenergic blocker (alpha-blocker). Its mechanism involves blocking specific receptors in the smooth muscle tissues of blood vessels and the prostate, which causes those muscles to relax. This action results in lower blood pressure and improved urinary flow.


Q: Do studies show Terasin is effective for its stated purpose?

Clinical trials for BPH documented changes in patient-reported symptom scores and peak urinary flow rates compared to placebo. Studies for hypertension also recorded a documented reduction in blood pressure measurements.


Q: Are there specific symptoms that require immediate medical attention while on Terasin?

Official documents highlight several serious adverse reactions, including syncope (fainting) and priapism (a prolonged, painful erection). These events are classified as clinically significant and are highlighted in the official information for immediate awareness.


Q: How is the safety profile of Terasin generally described?

The safety profile is largely defined by adverse reactions related to its alpha-1 blocking effects. The most commonly reported side effects observed in clinical trials included dizziness, headache, fatigue, and postural hypotension (low blood pressure upon standing).


Q: Is Terasin considered a controlled substance?

Terasin (Terazosin Hydrochloride) is a prescription medicine but is not classified or scheduled as a controlled substance under the U.S. Controlled Substances Act (CSA).


Q: Is Terasin the same type of medicine as [similar-sounding drug name]?

Terasin is formally classified as a selective alpha-1 adrenergic receptor antagonist, placing it within the alpha-blocker class of medications. The official label notes that Terasin's action is similar to other alpha antagonists in this drug class.


Q: Why do doctors prescribe Terasin for [less common use]? (If applicable)

Official regulatory documents only contain information for the two officially approved indications: the treatment of symptoms associated with Benign Prostatic Hyperplasia (BPH) and the management of essential hypertension (high blood pressure). Information on other uses is not detailed in the official label.


Q: Does Terasin cause weight gain or loss?

In official clinical trials for BPH, weight gain was reported as an uncommon side effect, affecting a small percentage of patients (0.5%). Weight loss was not specifically reported in the incidence tables for common or uncommon effects.


Q: Is it normal to feel [mild side effect] when starting Terasin?

Yes. Common side effects reported during clinical trials, such as dizziness or fatigue, are generally most likely to occur shortly after the initial dose is taken, when therapy is restarted after a pause, or when the dosage is increased.


Q: Can I use Terasin if I also take a daily supplement like [popular supplement]?

The official label does not specifically list interactions with most dietary supplements. However, because Terasin can lower blood pressure, combining it with any other agent that also lowers blood pressure may increase the risk of hypotension. Official information suggests informing a healthcare professional about all co-administered medicines and supplements.


Q: Is there a maximum amount of time Terasin is intended to be used?

The official product label does not set an absolute limit on the duration of use. Clinical evidence includes long-term open-label studies that monitored patients for the maintenance of response over several years (up to 3 to 4.5 years).


Q: Is Terasin safe for people over 65 years old?

Official information advises caution for use in older adults. This is due to the documented increased risk of severe postural hypotension (a drop in blood pressure when standing up) and related falls reported in this age group.


Q: Why does the Terasin label mention [specific ingredient]?

The Terasin label lists both the active ingredient (Terazosin Hydrochloride) and various inactive ingredients, such as lactose monohydrate. These inactive components are necessary for the product's formulation into a capsule or tablet but do not contribute to the medicine's therapeutic effect.


Q: How long has Terasin been on the market?

The active compound, Terazosin Hydrochloride, was first approved by the U.S. Food and Drug Administration (FDA) in 1987 for the treatment of hypertension.


Q: Can I take Terasin if I have a history of [common mild condition]?

Decisions regarding use with specific medical history are made by a healthcare professional, as official documents define eligibility based on strict contraindications (like micturition syncope) and specific organ cautions.


Q: What information is available about discontinuing Terasin?

If the medication is stopped for several days or longer, official documents state that therapy must be re-instituted at the initial 1 mg dose, and the full titration process must be repeated. Stopping the medicine can also lead to a return of the symptoms it was managing.


Q: What is the difference between the brand name and generic Terasin?

The official brand name for Terasin is Hytrin. The term Terazosin Hydrochloride is the generic name for the active chemical ingredient, which is available both in its original branded formulation and as a generic medicine.


Q: Is Terasin available as a generic medicine?

Yes, Terasin (Terazosin Hydrochloride) is widely available in generic form, in addition to its original branded formulation.


Q: Are there any known interactions between Terasin and herbal remedies?

The official product label does not specifically list herbal remedies in its interaction tables. However, regulatory sources generally caution against combining Terasin with any agent that may contribute to an additive blood pressure lowering effect.


Q: Does Terasin contain lactose or gluten?

Official product information confirms that Terasin capsules contain lactose monohydrate as an inactive ingredient. The official label does not contain a specific statement regarding the presence or absence of gluten.


Q: How does Terasin's use relate to [specific symptom/condition category]?

The official uses for Terasin are strictly for the treatment of symptoms associated with Benign Prostatic Hyperplasia (BPH) and the management of essential hypertension (high blood pressure).


Q: Is Terasin considered a 'strong' medicine?

The medication is factually defined by its class as a selective alpha-1 adrenergic receptor antagonist. Its effect is related to its dose-dependent ability to block specific receptors, which results in the relaxation of smooth muscle.


Q: Are there any special warnings for people taking Terasin?

Yes. Official documents highlight specific warnings, including the documented risk of developing Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery and the need for caution when co-administered with certain other drugs, like PDE-5 inhibitors.


Q: What is the maximum number of doses per day mentioned in the official information?

While the medication is generally taken once daily, the official dosing section notes that for essential hypertension, the total daily dose may be divided and administered as a twice-daily regimen if the blood pressure lowering effect diminishes significantly over 24 hours.

How should Terasin be stored and disposed of?

How to Store and Dispose of Terasin

Terasin (Terazosin Hydrochloride) must be stored under specific, officially documented conditions to maintain product stability and safety. This information is derived from regulatory labeling.

Storage Requirements

Terasin capsules must be stored at Controlled Room Temperature, typically maintained between 15 C and 30 C (59 F and 86 F). The medication must be protected from light and moisture and should be kept in a tight, light-resistant container with a child-resistant closure. It is mandatory to keep this and all medication out of the reach of children.

Disposal Instructions

Official guidelines recommend using a drug take-back program as the preferred method for disposing of unused or expired Terasin. If a take-back option is unavailable, the medication can be discarded in the household trash after mixing it with an undesirable substance (e.g., dirt or used coffee grounds) and sealing the mixture in a container. Terasin is not on the list of medicines approved by the FDA for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Terasin found in:

A-Z Index: